RS-533 is a novel carbapenem antibiotic. Its activity was compared with that of imipenem and the new cephalosporins, aztreonam, piperacillin, and tobramycin. RS-533 had activity comparable to that of imipenem, inhibiting the majority of the Enterobacteriaceae, streptococci, staphylococci, and Bacteroides species at concentrations of -2 ,ug/ml. RS-533 inhibited Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens resistant to ceftazidime, aztreonam, and cefoperazone, but RS-533 did not inhibit all methiciflinresistant Staphylococcus aureus or Pseudomonas maltophilia. It inhibited tobramycin-resistant members of the Enterobacteriaceae and Pseudomonas aeruginosa. RS-533 was stable against attack by common chromosomal and plasmid-mediated beta-lactamases and was an effective inhibitor of many beta-lactamases.
Many new beta-lactam antimicrobial agents have been introduced into clinical practice in the past decade. One class of compounds which has been of particular interest is the carbapenems. Imipenem, a thienamycin, has been extensively studied and is extremely useful in the treatment of a variety of infections (1, 2, 6) . RS-533 ( Fig. 1) is a new carbapenem. This agent differs significantly from imipenem, which has a basic alkythio side chain attached to the five-membered ring. We evaluated the antibacterial activity and beta-lactamase stability of RS-533 in comparison with those of other antimicrobial agents with particular reference to its activity against organisms resistant to other betalactam agents.
MATERIALS AND METHODS
Microorganisms. Gram-positive and gram-negative bacteria used in this study were clinical isolates from three hospitals in the Columbia University system. The isolates were specifically collected because of resistance to betalactam agents and aminoglycosides.
Antimicrobial agents. Standard antimicrobial powders were provided as follows: RS-533 from Sankyo International Corp., Tokyo, Japan; ceftazidime from Glaxo, Inc., Re Susceptibility to RS-533 of five isolates of each of several bacterial species was determined by broth dilution technique. Tubes (1 ml) containing serial twofold dilutions of the compound in Mueller-Hinton broth were inoculated with log-phase organisms to yield a final inoculum of 5 x 105 CFU/ml. Tubes were incubated for 18 h at 35°C and inspected for lack of turbidity. Samples of 0.01 ml were removed to antibiotic-free plates which were incubated for 24 h at 35C. The MBC, defined as a 99.9% reduction in the initial inoculum, was determined by the method of Pearson et al. (7) , assuming a 5% pipetting error.
Beta-lactamase assays and inhibition studies. The presence of beta-lactamases in clinical isolates was determined by the nitrocefin assay (5). The beta-lactamases used for the evaluation of the stability of the compound were either purified enzymes or partially purified enzymes as previously described (5 Organisms were incorporated into agar containing antibiotic at eight ti,mes the MIC. Organisms were isolated, and resistance was confirm,ed by agar dilution.
RESULTS
The results of agar susceptibility studies against gramnegative aerobic bacteria are shown in Table 1 . RS-533 had broad antibacterial activity inhibiting the majority of members of the Enterobacteriaceae and Pseudomonas spp., with the exception of Pseudomonas maltophilia, at concentrations of s2 ,ug/ml. RS-533 overall had activity similar to that of imipenem with minor differences in MICs noted for individual isolates. In general, RS-533 had activity similar to thAt of ceftazidime, except against Proteus spp., where ceftazidime was more active, and against Providencia spp., where a number of agents had equal activity, with aztreonam the most active. RS-533 inhibited at 2 ,ug/ml all the Klebsiella spp., Escherichia coli, and Proteus spp. which were resistant to cefoperazone and to piperacillin (MIC . 128 p.g/ml). It also inhibited the majority of the tobramycin-resistant Enterobacteriaceae and P. aeruginosa at c8 ,ug/ml.
Similar to imipenem, RS-533 inhibited E. cloacae and C. freundii which were resistant to ceftazidime, cefoperazone, and aztreonam. RS-533 was more active than cefoperazone, cefoxitin, or aztreonam against S. marcescens. RS-533, imipenem, and ceftazidime were the most active agents tested against the highly resistant P. aeruginosa and the Acinetobacter spp., but ceftazidime inhibited some of the P. maltophilia isolates resistant to RS-533 and imipenem. the JK group were resistant, as they were to imipenem and cefotaxime. RS-533 had activity comparable to that of imipenem against Bacteroides species, and it inhibited Clostridium perfringens at s1 ,ug/ml, but the MICs for Clostridium difficile were 8 ,ug/ml. Overall, th"e activities of imipenem and RS-533 were similar against the various anaerobes tested. RS-533 inhibited the majority of Fusobacterium spp. (five isolates), Eubacterium spp. (six isolates), peptococci (five isolates), and peptostreptococci (five isolates) at s0.015 to 2 ,ug/ml. It inhibited Bifidobacterium sp. at 0.03 ,ug/ml (one isolate), Lactobacillus acidophilus at 0.03 pug/ml (two isolates), Propionibacterium sp. at s0.015 ,ug/ml (three isolates), and Veillonella parulla at <0.015 ,ug/nil (one isolate).
Broth dilution studies. MICs of RS-533 against E. coli, Klebsiella pneumoniae, E. cloacae, S. marcescens, Morganella morganii, S. auretus, and P. aeruginosa (five isolates of each) were comparable to those determined by agar dilution. RS-533 was bactericidal at concentrations identical or eqtual to fourfold above the MIC for 31 of the 35 strains, and the MBCs for S. marcescens (one isolate), M. morganii, (one isolate), and P. aeruginosa (two isolates) were more than fourfold above the MICs. S. faecalis (five isolates) required MBCs of 64 ,ug/ml compared with MICs of 1 ,ug/ml, but the susceptible methicillin-resistant S. aureus required MBCs of 2 p.g/ml compared with MICs of 0.25 ,ug/ml, even when the assays were performed in the presence of 5% NaCl and plates were held for 30 h.
The effect of inoculum size is shown in Table 3 . There was an increase in MICs at 107 CFU which was most marked for a Enzymes were preincubated with RS-533 at the indicated concentrations for 10 min, and nitrocefin was added at a concentration of 100 FM.
S. marcescens but was also found for P. aeruginosa, M. morganii, and E. cloacae. The MICs for the susceptible, methicillin-resistant S. aureus did not exceed 2 ,ug/ml at 107 CFU.
Beta-lactamase stability. RS-533 was extremely stable against attack by plasmid beta-lactamases of the TEM, SHV-1, OXA-1, -2, -3, and PSE-1, -2, -3, and -4 types. It also was not hydrolyzed by enzymes from organisms containing chromosomally mediated Richmond-Sykes type Ta betalactamases in E. cloacae, C. freundii, and M. morganii. Neither S. aureus nor Bacteroides fragilis beta-lactamases hydrolyzed RS-533, and there was no hydrolysis of RS-533 by Proteus vulgaris or Klebsiella oxytoca beta-lactamases, which hydrolyze cefotaxime and aztreonam, respectively.
R.S-533 inhibited all of the organisms possessing the aforementioned various plasmid and chromosomal betalactamases at .8 ,ug/ml. Comparative MICs of other agents were as follows: cefoperazone for P. aeruginosa containing PSE-4, 128 ,ug/ml; aztreonam for K. oxytoca, 16 jig/ml; and cefotaxime for E. cloacae P99, 128 ,g/lml. RS-533 inhibited at 4 ,ug/ml six isolates of P. aeruginosa derepressed for beta-lactamase production and. at 0.5 ,ug/ml isolates of E.
cloacae (six isolates) and C. freundii (nine isolates), which were derepressed for production of beta-lactamase. The MICs for cefotaxime and ceftazidime were 8 to >32 ,ug/ml for these strains.
RS-533 was an effective inhibitor of both plasmid and chromosomal beta-lactamases (Table 4) , particularly of the TEM-1 enzyme and the type Ic enzymes. Inhibition of K-1 and the Sabath-Abraham P. aeruginosa beta-lactamases was less efficient than that of the plasmid enzymes.
RS-533 induced beta-lactamase activity in E. cloacae 10469 and P. aeruginosa 10524. The beta-lactamase activity induced in P. aeruginosa 10524 by RS-533 was 1,860 U/mg per min compared with 176 U/mg per mim for cefoxitin and 168 U/mg per min for moxalactatn. Uninduced activity was 9 U/mg per ml. For E. cloacae 10469 RS-533 produced 20,930 U/mg per min, cefoxitin produced 153 U/mg per min, and moxalactam produced 293 U/mg per min. Uninduced activity was 38 U/mg per ml. RS-533 was 10-fold more active as an inducer than was cefoxitin or moxalactam for P. aeruginosa 10524 and 100-fold more active for E. cloacae 10469.
However, RS-533 remained,active against strains in which it induced beta-lactamase with MICs of .2 p g/ml. Induction was similar with two and four times the MIC. Spontaneous resistance to RS-533 at eight times the MIC could not be selected by plating 109 CFU, whereas it was possible to select strains resistant to cefoperazone, aztreonam, and ceftazidime. RS-533 inhibited these strains selected for resistance (Table 5) . DISCUSSION Thienamycin, a product of Streptonyces cattleya, was discovered some 8 years ago, but it was an unstable sub- stance (1) . Imipenem is a useful amidine derivative of thienamycin that inhibits many bacteria and is betalactamase stable (1, 3, 6, 8, 9) . RS-533 is a novel carbapenem which differs chemnically from imipenem, which contains a basic alkythio side chain attached to the five-membered ring. In this study, it had in yitro activity comparable to that of imipenem against members of the Enterobacteriaceae, P. aeruginosa, B. fragilis, staphylococci, and hemolytic streptococci. RS-533 did not inhibit all methicillin-resistant staphylococci, but it actually was more active than imipenem against some isolates. RS-533, like imipenem, inhibited organisms such as E. cloacae and P. aeruginosa possessing derepressed chromosomal beta-lactamases which are resistant to ceftazidime, cefoperazone, and aztreonam. This may be related to easy entry through the cell wall due to small size or its probable binding to PBP2 and Ib in such species (1, 4) . RS-533 also inhibited Acinetobacter species which are resistant to most beta-lactam agents except imipenem. Furthermore, RS-533 inhibited Enterobacteriaceae and P. aeruginosa resistant to tobramycin as does imipenem. The sole species which were resistant to RS-533, similar to imipenem, were P. maltophilia and some methicillin-resistant staphylococci..
RS-533 was bactericidal near the MICs for E. coli, K. pneumoniae, E. cloacae, S. marcescens, M. morganii, and methicillin-susceptible S. aureus. Increasing the inoculum size to 107 CFU did not increase the mean MICs above 10 ,ug/ml.
RS-533 was stable against attack by most beta-lactamnases and Was an effective inhibitor of a number of plasmid and chromosomal beta-lactamases. Like imipenem and the penem FCE 22101, RS-533 was an effective inhibitor of TEM and SHV-1 beta-lactamases (6, 10) . Unlike many of the aminothiazolyl cephalosporins, RS-533 was a poor inhibitor of K. oxytoca K-1, P. aeruginosa PSE-4, and the SabathAbraham enzyme of P. aeruginosa.
The properties of RS-533 shown in this study demonstrate that variation in the carbapenem structure can yield highly active agents (3) . Studies of the activity of RS-533 against the rare isolates of Bacteroides spp. and of Bacillus cereus which hydrolyze imipenem should be performed to determine whether this agent overcomes these defects of imipenem. Further studies of the stability of RS-533 to renal dipeptidases and of its potential for nephrotoxicity are required since imipenem in the absence of cilastatin has these two flaws (1) . Overall, the results of this study of RS-533 show that its in vitro activity is comparable to that of other carbapenems and penems (1, 10) .
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